QuidelOrtho (NASDAQ:QDEL) Updates FY 2025 Earnings Guidance

Key Points

• QuidelOrtho updated its FY 2025 earnings guidance, projecting earnings per share (EPS) between 2.070-2.570 while revenue guidance is set at $2.6 billion-$2.8 billion.
• The company's shares opened at $25.95, experiencing a 4.2% decline on the day of the guidance announcement.
• Despite a recent earnings report showing a negative net margin of 16.10%, QuidelOrtho surpassed expectations with an EPS of $0.12 against a consensus estimate of $0.01.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 2.070-2.570 for the period, compared to the consensus estimate of 2.405. The company issued revenue guidance of $2.6 billion-$2.8 billion, compared to the consensus revenue estimate of $2.7 billion.

QuidelOrtho Trading Down 4.2%

Shares of QDEL stock opened at $25.95 on Friday. QuidelOrtho has a fifty-two week low of $22.05 and a fifty-two week high of $49.45. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 1.12. The stock has a 50 day simple moving average of $27.55 and a two-hundred day simple moving average of $31.96. The company has a market cap of $1.76 billion, a P/E ratio of -3.97 and a beta of -0.04.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.11. The company had revenue of $613.90 million during the quarter, compared to analyst estimates of $612.36 million. QuidelOrtho had a negative net margin of 16.10% and a positive return on equity of 5.29%. QuidelOrtho's revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.07) EPS. Research analysts forecast that QuidelOrtho will post 2.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on QDEL shares. Jefferies Financial Group raised shares of QuidelOrtho from a "hold" rating to a "buy" rating and set a $44.00 price objective on the stock in a research report on Thursday, May 8th. UBS Group reduced their price objective on QuidelOrtho from $29.00 to $26.00 and set a "neutral" rating for the company in a research note on Thursday, August 7th. JPMorgan Chase & Co. lowered their target price on QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating on the stock in a research report on Monday, April 21st. Citigroup reduced their price target on shares of QuidelOrtho from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Finally, Wall Street Zen downgraded shares of QuidelOrtho from a "buy" rating to a "hold" rating in a report on Saturday, July 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, QuidelOrtho presently has an average rating of "Hold" and an average price target of $42.17.

Hedge Funds Weigh In On QuidelOrtho

Several large investors have recently bought and sold shares of QDEL. EverSource Wealth Advisors LLC raised its holdings in shares of QuidelOrtho by 250.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company's stock valued at $93,000 after purchasing an additional 2,309 shares during the last quarter. Amundi bought a new stake in QuidelOrtho in the 2nd quarter worth about $540,000. Focus Partners Wealth increased its stake in QuidelOrtho by 210.9% in the 1st quarter. Focus Partners Wealth now owns 20,454 shares of the company's stock valued at $715,000 after buying an additional 13,876 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of QuidelOrtho by 161.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,017 shares of the company's stock worth $980,000 after buying an additional 20,985 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of QuidelOrtho in the 2nd quarter worth approximately $1,071,000. 99.00% of the stock is currently owned by institutional investors.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.